DeepMed Research

EISAI INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations

Phase 2

Withdrawn

Conditions: Parkinson's Disease

First Posted Date: 2007-03-23

Last Posted Date: 2013-10-31

Lead Sponsor: Eisai Inc.

Registration Number: NCT00451633

Locations: 🇩🇪
St. Josef Hospital, Bochum, Germany
🇮🇹
U.O. Riabilitazione Neuromotoria, IRCCS San Raffaele Pisana, Roma, Italy
🇮🇹
CESI - Centro Ricerche Cliniche - Fondazione Universita degli Studi, Chieti, Italy

and more 2 locations

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Phase 3

Terminated

Conditions: Refractory Partial Onset Seizures

Interventions: Drug: Rufinamide

First Posted Date: 2007-03-19

Last Posted Date: 2019-11-22

Lead Sponsor: Eisai Inc.

Target Recruit Count: 286

Registration Number: NCT00448539

Locations: 🇺🇸
Comprehensive Epilepsy Care Center for Children and Adults, Chesterfield, Missouri, United States
🇺🇸
Child Neurology Associates, PC, Atlanta, Georgia, United States
🇺🇸
John Hopkins Hospital, Dept. of Neurology, Baltimore, Maryland, United States

and more 24 locations

Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism

Phase 4

Completed

Conditions: Pulmonary Embolism

First Posted Date: 2007-03-01

Last Posted Date: 2018-10-18

Lead Sponsor: Eisai Inc.

Target Recruit Count: 5

Registration Number: NCT00442234

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Phase 2

Completed

Conditions: Chronic Idiopathic Thrombocytopenic Purpura
Purpura, Thrombocytopenic, Idiopathic

Interventions: Drug: Avatrombopag tablets
Drug: Placebo

First Posted Date: 2007-02-28

Last Posted Date: 2018-03-07

Lead Sponsor: Eisai Inc.

Target Recruit Count: 64

Registration Number: NCT00441090

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
University of California Irvine Cancer Center, Orange, California, United States
🇺🇸
Florida Cancer Institute, New Port Richey, Florida, United States

and more 22 locations

A Study of E2007 In Patients With Parkinson's Disease

Phase 2

Terminated

Conditions: Parkinson's Disease

Interventions: Drug: E2007

First Posted Date: 2007-01-26

Last Posted Date: 2013-02-11

Lead Sponsor: Eisai Inc.

Target Recruit Count: 25

Registration Number: NCT00427011

Locations: 🇺🇸
Brain Matters Research, Delray Beach, Florida, United States
🇺🇸
Suncoast Neuroscience Associates, Inc., St. Petersburg, Florida, United States
🇺🇸
Raleigh Neurology Associates, Raleigh, North Carolina, United States

and more 6 locations

E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Soft Tissue Sarcoma

Interventions: Drug: E7389

First Posted Date: 2006-12-19

Last Posted Date: 2017-04-26

Lead Sponsor: Eisai Inc.

Target Recruit Count: 128

Registration Number: NCT00413192

Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers

Phase 4

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo Comparator
Drug: Experimental 1

First Posted Date: 2006-11-23

Last Posted Date: 2014-07-14

Lead Sponsor: Eisai Inc.

Target Recruit Count: 240

Registration Number: NCT00403520

Locations: 🇫🇷
CHU Gui de Chauliac, Montpellier cedex, France

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

Phase 3

Completed

Conditions: Obesity

Interventions: Drug: Lorcaserin 10 mg BID
Drug: Matching Placebo BID

First Posted Date: 2006-11-02

Last Posted Date: 2019-10-02

Lead Sponsor: Eisai Inc.

Target Recruit Count: 3182

Registration Number: NCT00395135

Locations: 🇺🇸
Arena Pharmaceuticals, Inc., San Diego, California, United States

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Physician's Choice
Drug: E7389

First Posted Date: 2006-10-17

Last Posted Date: 2020-01-07

Lead Sponsor: Eisai Inc.

Target Recruit Count: 762

Registration Number: NCT00388726

Locations: 🇺🇸
Montana Cancer Specialists, Missoula, Montana, United States
🇺🇸
Bellflower Satellite, Bellflower, California, United States
🇺🇸
Weill Cornell Breast Cancer Center, New York, New York, United States

and more 118 locations

A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

Phase 1

Completed

Conditions: Breast Cancer
Ovarian Cancer
Prostate Cancer
Colon Cancer
Renal Cancer

Interventions: Drug: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)

First Posted Date: 2006-09-27

Last Posted Date: 2013-05-14

Lead Sponsor: Eisai Inc.

Target Recruit Count: 22

Registration Number: NCT00381173

Locations: 🇺🇸
M. D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy